Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bromocriptine for Food Intake in High Risk T2DM
NCT05405244Phase 3Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Sep 2017
- Primary completion
- Sep 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of bromocriptine in type 2 diabetes mellitus (T2DM), obesity, sponsored by University of North Carolina at Chapel Hill. Started Sep 2017; status: completed.
02
Drugs
bromocriptine
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05405244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05405244.